niacin has been researched along with Hyperphosphatemia in 12 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niacin has profound and unique effects on lipid metabolism." | 5.36 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. ( Ahmed, MH, 2010) |
| "We performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268)." | 5.14 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. ( Bostom, AG; Hanlon, WA; Kuznetsova, O; Maccubbin, D; Tipping, D, 2010) |
| "Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders." | 2.77 | Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. ( Ahmadi, F; Khatami, MR; Lessan-Pezeshki, M; Shamekhi, F, 2012) |
| " As for safety end points (including mortality, adverse events, and all-cause discontinuation), almost all agents were equivalent in term of mortality and all-cause discontinuation except in the comparison between iron-based phosphate-binding agents and placebo." | 2.58 | Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( Bai, Q; Guo, H; Li, Y; Liu, H; Yang, X; Zhang, X, 2018) |
| "Hyperphosphatemia is an important modifiable risk factor in the dialysis population because it is linked to increased mortality." | 2.45 | Niacin and analogs for phosphate control in dialysis--perspective from a developing country. ( Sampathkumar, K, 2009) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| "Niacin has profound and unique effects on lipid metabolism." | 1.36 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. ( Ahmed, MH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, X | 1 |
| Bai, Q | 1 |
| Li, Y | 1 |
| Liu, H | 1 |
| Guo, H | 1 |
| Zhang, X | 1 |
| Drüeke, TB | 1 |
| Massy, ZA | 1 |
| Liu, X | 1 |
| Yang, R | 1 |
| Dai, B | 1 |
| Zhang, H | 1 |
| Wang, J | 1 |
| Ma, N | 1 |
| Rennick, A | 1 |
| Kalakeche, R | 1 |
| Seel, L | 1 |
| Shepler, B | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| Sampathkumar, K | 1 |
| Bostom, AG | 2 |
| Maccubbin, D | 1 |
| Tipping, D | 1 |
| Kuznetsova, O | 1 |
| Hanlon, WA | 1 |
| Ahmed, MH | 1 |
| Ahmadi, F | 1 |
| Shamekhi, F | 1 |
| Lessan-Pezeshki, M | 1 |
| Khatami, MR | 1 |
| Musso, CG | 1 |
| Reynaldi, MJ | 1 |
| Aparicio, C | 1 |
| Frydenlund, S | 1 |
| Imperiali, N | 1 |
| Algranati, L | 1 |
| Restrepo Valencia, CA | 1 |
| Cruz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis[NCT03163576] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacin and Hyperphosphatemia
| Article | Year |
|---|---|
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Topics: Bile Acids and Salts; Calcium; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Iron; | 2018 |
Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Topics: Animals; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacin; Niacinamide; Peritoneal Dialysi | 2013 |
Niacin and analogs for phosphate control in dialysis--perspective from a developing country.
Topics: Administration, Oral; Clinical Trials as Topic; Cost Savings; Developing Countries; Dose-Response Re | 2009 |
2 trials available for niacin and Hyperphosphatemia
| Article | Year |
|---|---|
Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
Topics: Aged; Biomarkers; Calcium; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug T | 2010 |
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Calcium; Chelating Agents; Female; Humans; Hyperphosp | 2012 |
7 other studies available for niacin and Hyperphosphatemia
| Article | Year |
|---|---|
Lowering Expectations with Niacin Treatment for CKD-MBD.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Minerals; Motivation; N | 2018 |
Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.
Topics: Antimetabolites; Gastrointestinal Agents; Humans; Hyperphosphatemia; Niacin; Renal Dialysis | 2018 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |
Binder blinders-niacin of omission?
Topics: Animals; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Humans; Hyperphosphatem | 2010 |
Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials.
Topics: Clinical Trials as Topic; Dyslipidemias; Humans; Hyperphosphatemia; Hypolipidemic Agents; Kidney Fai | 2010 |
Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients.
Topics: Delayed-Action Preparations; Humans; Hyperphosphatemia; Niacin; Peritoneal Dialysis; Treatment Outco | 2008 |
[Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
Topics: Chronic Disease; Female; Humans; Hyperlipidemias; Hyperphosphatemia; Hypolipidemic Agents; Kidney Di | 2008 |